EVOK Logo.jpg
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases,...
EVOK Logo.jpg
Evoke Pharma Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h05 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
EVOK Logo.jpg
Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021
03 nov. 2021 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases,...
Evoke Pharma, Inc.
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
20 oct. 2021 08h30 HE | Evoke Pharma, Inc.
Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in...
EVOK Logo.jpg
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI
29 sept. 2021 08h30 HE | Evoke Pharma, Inc.
Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif., Sept. 29, 2021 (GLOBE...
EVOK Logo.jpg
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
01 sept. 2021 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
EVOK Logo.jpg
Evoke Pharma Reports Second Quarter 2021 Financial Results
12 août 2021 16h05 HE | Evoke Pharma, Inc.
Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif., Aug....
EVOK Logo.jpg
Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021
05 août 2021 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases,...
EVOK Logo.jpg
Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders’ (IFFGD) August Gastroparesis Awareness Month
02 août 2021 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a...
EVOK Logo.jpg
Evoke Pharma Launches Gimoti® Patient and Physician Experience Program
14 juil. 2021 08h30 HE | Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...